Nuplazid Lawsuits

Nuplazid is a medication that is used to treat hallucinations caused by Parkinson’s disease. However, side effects of Nuplazid have been linked to an alarming number of adverse events and patient deaths, leading to serious questions about whether benefits outweigh the potential health risks and whether a Nuplazid recall may be necessary. 

STATUS OF NUPLAZID LAWSUITS: Following investigations by health experts and researchers, product liability lawyers reviewed whether financial compensation was available through a Nuplazid lawsuit for individuals who suffered serious injuries, deaths, or hallucinations after using the drug.

AboutLawsuits.com is no longer reviewing new claims involving Nuplazid side effects. This page is maintained for informational purposes only.

Nuplazid Lawsuit Overview

MANUFACTURER: Acadia Pharmaceuticals.

OVERVIEW: Nuplazid (pimavanserin) is an atypical antipsychotic used to prevent hallucinations experienced by Parkinson’s disease patients. The drug was just introduced by Acadia Pharmaceuticals in April 2016, after it was approved by the FDA through a fast track “Breakthrough Therapy” process.

During the first full year on the market, Nuplazid sales generated about $125 million in sales for Acadia Pharmaceuticals. However, increasing evidence seems to suggest that the drug maker may have failed to adequately research the potential side effects or warn about potential Nuplazid health risks users may face.

NUPLAZID DEATHS: According to reports submitted to the FDA’s Adverse Event Reporting System, thousands of Nuplazid problems and 700 deaths have been linked to use of the drug. While, the reports are not proof Nuplazid caused those deaths and injuries, at least 500 of the fatalities listed Nuplazid as the only suspect medication taken by the patient at the time.

Overall, the FDA has received nearly 6,000 Nuplazid incident reports since 2016, and the FDA announced in late April 2018 that it has launched a safety review of the drug.

The Institute for Safe Medication Practices (ISMP) issued a warning about Nuplazid safety signals in its November 2017 QuarterWatch report, indicating that the FDA had received 2,236 adverse event reports over the course of its first year on the market, including 244 deaths and signs that the drug may actually worsen hallucinations in some cases.

The problems also included reports of falls, insomnia, nausea, and fatigue.